Alternatively, trials of vantictumab (an anti-Frizzled antibody) + chemotherapy for the treatment of patients with HER2-negative breast cancer or pancreatic cancer closed early due to high rates of bone fracture.29-31. This evidence concerns the gene ERBB2 and breast carcinoma.